Genewiz Collaboration Spree Covers Ovarian Cancer Biomarkers, Next-Gen MDx
Genewiz, a CRO that specializes in genomic services, has really been making the rounds over the past couple days. Just this morning, the firm announced that it will be collaborating with the John Theurer Cancer Center at Hackensack University Medical Center with the goal of advancing ovarian cancer biomarker discovery research.
This research collaboration will reportedly enable analysis of ovarian cancer samples for the identification of biomarkers predicting prognosis and chemotherapy outcomes for ovarian cancer. Genewiz will process and analyze clinical samples supplied by the John Theurer Cancer Center in labs located at their global headquarters in South Plainfield, NJ.
"Working with Genewiz offers the confidence of proven competencies in comprehensive genomic analysis for cancer research, as well as the benefit of having a CLIA-certified, CAP-accredited laboratory for working with our clinical samples," said K. Stephen Suh, Ph.D., principal investigator at the John Theurer Cancer Center.
Meanwhile, on the other side of the globe, Genewiz will also be collaborating with KeyTest Diagnostics in an effort to establish clinical testing standards and the development of next-generation molecular diagnostics using genomics technologies in China. KeyTest Diagnostics is reportedly the first third-party medical testing center in Suzhou certified by Jiangsu Health Bureau.
"Partnering with KeyTest Diagnostics will enable Chinese customers to gain access to clinical tests that are critical to disease treatment and their overall health," stated Amy Liao, Ph.D., president and COO of Genewiz. "Together, we will have the ability to develop and introduce more clinical tests in China, thus helping to make a difference in the pursuit of scientific discoveries and better medicines around the globe."